A phase IIa study of radium-223 dichloride (Ra-223) alone or in combination with abiraterone acetate or enzalutamide in metastatic castration-resistant prostate cancer (mCRPC)

被引：0
|
作者：
Petrylak, D. P. [1 ]
Vaishampayan, U. N. [2 ]
Patel, K. R. [3 ]
Higano, C. S. [4 ]
Albany, C. [5 ]
Dawson, N. A. [6 ]
Mehlhaff, B. A. [7 ]
Quinn, D. I. [8 ]
Nordquist, L. T. [9 ,10 ]
Wagner, V. J. [11 ]
Shen, J. [12 ]
Trandafir, L. [13 ]
Sartor, O. [14 ]
机构：
[1] Yale Canc Ctr, Dept Med Oncol, New Haven, CT USA
[2] Karmanos Canc Inst, Oncol, Detroit, MI USA
[3] Arizona Inst Urol, Urol, Tucson, AZ USA
[4] Univ Washington, Seattle Canc Care Alliance, Med, Seattle, WA 98195 USA
[5] Indiana Univ, Oncol, Indianapolis, IN 46204 USA
[6] Georgetown Univ, Dept Med, Washington, DC USA
[7] Oregon Urol Inst, Gen Urol, Springfield, OR USA
[8] Univ Southern Calif, Norris Comprehens Canc Ctr, Translat & Clin Sci Program Oncol, Los Angeles, CA USA
[9] Urol Canc Ctr, Med Oncol, Omaha, NE USA
[10] GU Res Network, Omaha, NE USA
[11] Bayer Consumer Care Switzerland, Global Clin Dev Oncol, Basel, Switzerland
[12] Bayer HealthCare Pharmaceut, Clin Stat, Whippany, NJ USA
[13] Bayer Consumer Care Switzerland, R&D, Basel, Switzerland
[14] Tulane Univ, Hematol Oncol, New Orleans, LA 70118 USA
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
870P
引用
收藏
页码：340 / 341
页数：2
相关论文
共 50 条
  • [1] A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/ prednisone or enzalutamide
    Petrylak, D. P.
    Vaishampayan, U. N.
    Patel, K. R.
    Higano, C. S.
    Albany, C.
    Dawson, N. A.
    Mehlhaff, B. A.
    Quinn, D., I
    Nordquist, L. T.
    Wagner, V. J.
    Siegel, J.
    Trandafir, L.
    Sartor, O.
    [J]. ESMO OPEN, 2021, 6 (02)
  • [2] Fracture risk after radium-223 (Ra-223) in metastatic castration resistant prostate cancer (mCRPC).
    Alonzi, Roberto
    Parker, Chris C.
    Tunariu, Nina
    Koh, Dow-Mu
    Staffurth, John
    Blackledge, Matthew D.
    Padhani, Anwar R.
    Tree, Alison
    Stidwill, Helen
    Finch, Jessica
    Chatfield, Peter
    Perry, Sophie
    Tovey, Holly
    Hall, Emma
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [3] A randomized phase 2 study investigating 3 dosing regimens of radium-223 dichloride (Ra-223) in bone metastatic castration-resistant prostate cancer (mCRPC).
    Sternberg, Cora N.
    Saad, Fred
    Graff, Julie Nicole
    Peer, Avivit
    Vaishampayan, Ulka N.
    Leung, Eugene
    Rosenbaum, Eli
    Gurney, Howard
    Epstein, Richard
    Davis, Ian D.
    Wu, Bingyan
    Trandafir, Lucia
    Wagner, Volker Jean
    Hussain, Maha
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] Combination treatment with radium-223 (223Ra) and enzalutamide (enza) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the REASSURE study
    Tombal, B.
    Goebell, P. J.
    Shore, N. D.
    George, D. J.
    Pinto, A.
    Sartor, O.
    Meltzer, J.
    Verholen, F.
    Schmall, A.
    Saad, F.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S984 - S984
  • [5] Pain efficacy with radium-223 (Ra-223) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the PARABO observational study
    Palmedo, H.
    Ahmadzadehfar, H.
    Eschmann, S.
    Selkinski, I.
    Straube, F.
    Niesen, A.
    Schoenberger, J.
    Barsegian, V.
    Liepe, K.
    Mottaghy, F. M.
    Guan, R.
    Pinkert, J.
    Buetikofer, S.
    Herrmann, K.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S641 - S641
  • [6] ERA 223: A phase 3 trial of radium-223 dichloride (Ra-223) in combination with abiraterone acetate (abiraterone) and prednisone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naive patients (pts) with bone predominant metastatic castration-resistant prostate cancer (mCRPC).
    Smith, Matthew Raymond
    Parker, Chris
    Tombal, Bertrand F.
    Miller, Kurt
    Saad, Fred
    Fang, Fang
    Zhang, Amily
    Kornacker, Martin
    Higano, Celestia S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [7] Pain efficacy with radium-223 (Ra-223) in the REASSURE global, prospective, observational study of men with metastatic castration-resistant prostate cancer (mCRPC)
    Higano, C. S.
    Dizdarevic, S.
    Sundar, S.
    Agarwal, N.
    Essler, M.
    Song, D.
    George, S.
    Shore, N. D.
    Kurtinecz, M.
    Verholen, F.
    Sandstrom, P.
    Sartor, O.
    George, D. J.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S640 - S641
  • [8] Pain evaluation in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) in the PARABO observation study
    Palmedo, H.
    Eschmann, S.
    Werner, A.
    Selinski, I.
    Moellers, M-O.
    Kalinovsky, J.
    Benson, A.
    Poeppel, T.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 : 336 - 336
  • [9] Fracture risk in men with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra 223)
    Hijab, A.
    Tunariu, N.
    Tovey, H.
    Alonzi, R.
    Tree, A.
    Staffurth, J.
    Blackledge, M.
    Padhani, A. R.
    Stidwill, H.
    Finch, J.
    Chatfield, P.
    Perry, S.
    Koh, D-M.
    Hall, E.
    Parker, C.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S539 - S539
  • [10] Combination Therapy With Radium-223 and Enzalutamide in Castration-Resistant Prostate Cancer
    Maughan, Benjamin L.
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (12) : 764 - 766
12345